Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BZM4
UPID:
ULBP3_HUMAN
Alternative names:
ALCAN-gamma; NKG2D ligand 3; Retinoic acid early transcript 1N
Alternative UPACC:
Q9BZM4; Q5VY82; Q8IZX5; Q8TE75
Background:
UL16-binding protein 3, also known as ALCAN-gamma, NKG2D ligand 3, and Retinoic acid early transcript 1N, plays a pivotal role in immune surveillance. It binds and activates the KLRK1/NKG2D receptor, a critical component in mediating natural killer cell cytotoxicity. This interaction is fundamental in the immune system's ability to recognize and eliminate malignant cells.
Therapeutic significance:
Understanding the role of UL16-binding protein 3 could open doors to potential therapeutic strategies. Its involvement in activating natural killer cells suggests its potential in cancer immunotherapy, offering a promising avenue for research and development in targeted cancer treatments.